Hydroxychloroquine as Oral Antidiabetic Agent During Coronavirus Pandemic

Anirban Majumder*

The coronavirus disease 2019 (COVID-19) is spreading rapidly. Hydroxychloroquine (HCQ), an old drug for treatment of malaria and autoimmune disease with acceptable safety, has shown promising but yet unproven effect against COVID-19 infection. HCQ is an approved agent by the Drug Controller General of India (DCGI) for the therapy of Type 2 Diabetes. In view of the fact that people with diabetes face higher chance of experiencing serious complications from COVID-19, HCQ may have preferential position as an antidiabetic agent during this crisis period.

Keywords:

Published on: May 7, 2020 Pages: 6-8

Full Text PDF Full Text HTML DOI: 10.17352/2455-5363.000027
CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos Universite de Paris UW Libraries SJSU King Library SJSU King Library NUS Library McGill DET KGL BIBLiOTEK JCU Discovery Universidad De Lima WorldCat VU on WorldCat